source
- Sofinnova Partners raises €725 million for second crossover fund targeting late-stage European biotech firmsSofinnova Partners announced the closing of its second crossover fund with €725 million ($815 million) in commitments. The fund is designed to fill the financing gap for late-stage European biopha…
- China adds CAR-T therapy to national insurance list, slashing price to $40,000China has added a CAR-T therapy to its National Reimbursement Drug List, cutting the price to $40,000. The reduction brings the treatment within the scope of basic medical insurance, improving aff…